Dupixent Lawsuit
Patients Taking Dupixent May Have Developed T-Cell Lymphoma
T-Cell Lymphoma Linked to Dupixent
Multiple peer-reviewed studies have linked Dupixent (dupilumab), a widely prescribed biologic injection, to an increased risk of developing cutaneous T-cell lymphoma (CTCL) — a rare and aggressive cancer affecting immune cells in the skin. A 2024 study published in JAMA Dermatology found approximately three times the risk of CTCL among Dupixent users, while a 2025 analysis found up to 4.5 times the increased risk. An independent analysis of FDA adverse-event data identified approximately 181,575 reports involving Dupixent, with CTCL reports occurring at a rate about 30 times higher for Dupixent users compared to all other medications.
Adding to the concern, because CTCL can closely mimic eczema — one of Dupixent’s primary indications — patients may have unknowingly continued treatment while their cancer silently advanced, delaying diagnosis and allowing the disease to progress.
What Is Dupixent?
Dupixent (dupilumab) is a biologic injectable medication manufactured by Sanofi and Regeneron Pharmaceuticals. It is approved by the FDA to treat moderate-to-severe atopic dermatitis (eczema), asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and prurigo nodularis.
Dupixent works by blocking two key proteins — interleukin-4 (IL-4) and interleukin-13 (IL-13) — that drive chronic inflammatory responses. It is administered as a subcutaneous injection, typically every two to four weeks, and has become one of the most widely prescribed biologics in the United States since its 2017 approval. Researchers now believe that Dupixent’s immune-modulating mechanism may unintentionally interfere with the body’s ability to detect or suppress cancerous T-cells, potentially triggering or accelerating undiagnosed CTCL in certain patients.
What Is Cutaneous T-Cell Lymphoma (CTCL)?
Cutaneous T-cell lymphoma is a rare form of non-Hodgkin lymphoma in which white blood cells called T-cells become cancerous and accumulate in the skin. In its early stages, CTCL closely resembles chronic skin conditions like eczema, causing redness, scaly patches, and persistent itching.
Because early CTCL symptoms are nearly indistinguishable from eczema, patients placed on Dupixent for an eczema diagnosis may unknowingly have had early-stage lymphoma — and continued Dupixent treatment may have masked their symptoms, accelerated disease progression, or delayed a proper cancer diagnosis. Treatment for CTCL can include radiation, targeted therapies, immunotherapy, and chemotherapy, depending on the stage and extent of disease at the time of diagnosis. If you took Dupixent and have been diagnosed with CTCL or another T-cell lymphoma, contact us today.
How AWKO Can Help Patients Diagnosed With T-Cell Lymphoma After Dupixent
For over 25 years, the AWKO firm has successfully represented more than 250,000 women and men in cases involving injuries caused by defective and dangerous drugs. Committed to fighting for justice, AWKO passionately advocates for victims’ rights, ensuring they receive the compensation they deserve.
You may qualify for the Dupixent lawsuit if you or a loved one:
- Were prescribed Dupixent (dupilumab) and took it for at least one month
- Were diagnosed with cutaneous T-cell lymphoma (CTCL), mycosis fungoides, or Sézary syndrome before or after taking Dupixent
- Did not have a prior diagnosis of Hodgkin’s lymphoma, non-Hodgkin lymphoma, leukemia, or non-follicular lymphoma before starting Dupixent
- Suffered delayed cancer diagnosis as a result of CTCL symptoms being mistaken for eczema while on Dupixent
- Lost a loved one to T-cell lymphoma connected to Dupixent use
If you or a loved one has been diagnosed with T-cell lymphoma after taking Dupixent, please contact us today or use the “Free Case Evaluation” form on this page to learn more about your legal rights.